Go to content

Understanding hepatopancreatobiliary cancer risks in a population-based primary sclerosing cholangitis-inflammatory bowel disease cohort

Share

Background and aims — Primary sclerosing cholangitis (PSC) is a pre-malignant condition with elevated risk of hepatopancreatobiliary cancers (HPBCa) and colorectal cancer (CRC) when inflammatory bowel disease (IBD) is present. We described cancer burden in a contemporary PSC–IBD cohort, and assessed rates of subsequent cancers, liver transplant, and death post-colectomy or post-cholecystectomy status.

Methods — Using linked health administrative databases, we calculated cause-specific cumulative incidences of HPBCa-related outcomes (diagnoses/deaths) and non-HPBCa-related transplant/death among individuals with PSC–IBD in Ontario, Canada (2002–2018), followed to 2021. Transition probabilities and transition intensity ratios (TIR) were evaluated using a multistate Markov model.

Results — Among 476 individuals with incident PSC–IBD, there was a 54% probability of remaining event-free at 10 years. Approximately 1 in 20 experienced an HPBCa-related outcome, and up to 1 in 4 had a non-HPBCa-related transplant/death. During follow-up, 13% experienced multiple events. Age was associated with HPBCa (HR 1.02, 95% CI 1.01–1.04), but not sex. Mortality occurred more frequently post-colectomy (TIR 3.08, 95% CI 1.7–5.59) and post-cholecystectomy (TIR 3.85, 95% CI 2.21–6.64) relative to event-free PSC–IBD, but there were no differences in post-surgery incidence of cancer or transplant.

Conclusions — While some individuals with PSC–IBD experienced an extended event-free disease course, a large proportion experienced disease-related cancer, colectomy, cholecystectomy, and transplant events. Higher mortality rates observed after surgery were likely related to underlying disease processes that motivated surgical intervention (eg, dysplasia/malignancy, refractory IBD), rather than the surgery itself. Understanding how PSC–IBD disease trajectories vary can inform individual management and patient counselling.

Information

Citation

Leung KK, Li W, Hansen B, Gulamhusein A, Lapointe-Shaw L, Ricciuto A, Benchimol EI, Flemming JA, Hirschfield GM. Hepatology. 2026; Feb 4 [Epub ahead of print].

View Source

Research Programs

Associated Sites